Helen Torley joins Onyx Pharmaceuticals
Takes the position of executive vp and chief commercial officer
Torley reports to Anthony Coles, president and chief executive officer, and take responsibility for all commercial activities related to Nexavar and the potential launch of carfilzomib, the development of the company's European commercial organisation, and initiatives to grow business and capabilities in the US and Europe.
Before joining Onyx, Torley spent nine years at Amgen where she most recently served as vice president and general manager of the Bone Health Business Unit, after leading the company's Nephrology Business Unit for five years.
From 1997 to 2002, she held various senior management positions at Bristol Myers Squibb.
Torley began her industry career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, overseeing phase IIIb and IV clinical studies across all therapeutic areas, including oncology.
You may also like
Ingredients
![UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny]()
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny
The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Pharmaceutical
![OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics]()
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics
The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
Pharmaceutical
![Pharma’s silent sustainability risk and the supply chain fix]()
Pharma’s silent sustainability risk and the supply chain fix
Pharma is making efforts to cut emissions from its own operations: shifting to renewables, upgrading facilities, streamlining logistics²⁰. But a significant share of emissions still hides outside the company’s direct control – yet in plain sight. Now, regulators and investors are turning their focus beyond the factory gates, deep into the value chain. What they’re finding is already reshaping the rules of competitiveness, capital access, and compliance. One of pharma’s most overlooked risks is quietly moving into the foreground. And the time to act is narrowing
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
